About Synthetic Biologics
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NYSEMKT
- Symbol: SYN
Companies Related to Synthetic Biologics:
- Previous Close: $0.74
- 50 Day Moving Average: $0.8376
- 200 Day Moving Average: $1.2306
- 52-Week Range: $92,172,000.00 - $0.73
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.71
- P/E Growth: 0.0000
- Market Cap: $67.85M
- Outstanding Shares: 92,172,000
- Beta: 1.39
What is Synthetic Biologics' stock symbol?
Synthetic Biologics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "SYN."
Where is Synthetic Biologics' stock going? Where will Synthetic Biologics' stock price be in 2017?
6 brokers have issued 1 year price targets for Synthetic Biologics' shares. Their predictions range from $5.00 to $6.00. On average, they expect Synthetic Biologics' share price to reach $5.45 in the next year.
When will Synthetic Biologics announce their earnings?
Synthetic Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns Synthetic Biologics stock?
Synthetic Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Third Security LLC (14.36%), MSD Partners L.P. (4.47%) and State Street Corp (1.04%). Company insiders that own Synthetic Biologics stock include Bartley Vaden Heath, Brendan Cannon, Christoper Martin and Randal J Kirk.
Who bought Synthetic Biologics stock? Who is buying Synthetic Biologics stock?
Synthetic Biologics' stock was purchased by a variety of institutional investors in the last quarter, including Third Security LLC, MSD Partners L.P. and State Street Corp. Company insiders that have bought Synthetic Biologics stock in the last two years include Bartley Vaden Heath, Brendan Cannon, Christoper Martin and Randal J Kirk.
How do I buy Synthetic Biologics stock?
Shares of Synthetic Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Synthetic Biologics stock cost?
One share of Synthetic Biologics stock can currently be purchased for approximately $0.75.